Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety and tolerability. Using this strategy, we are building a robust pipeline of ADC candidates with the potential to make a life-changing difference for people living with cancer. Our lead candidate, XMT-1536, is a first-in-class Dolaflexin ADC in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma.

Our experienced management team shares a strong commitment to scientific excellence and patient care, while also cultivating a highly collaborative and welcoming workplace. At Mersana, we have a passion for advancing therapies that make a significant impact in the lives of people living with cancer.


Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.


To create a world where all patients triumph over cancer.